Pyrazinamide resistance in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Abkhazia
- Pardini M.
- Varaine F.
- Hewison C.
- Iona E.
- Pataracchia M.
- Orefici G.
- Fattorini L.
- Oggioni M. R.
- Meacci F.
- D'Amato V.
- Andrew P. W.
- Barer M.
- Yesilkaya H.
- Rinder H.
- Rusch-Gerdes S.
- Niemann S.
- Orru G.
- Varaine F.
- Bonnet M.
- Jarosz T.
Publication date
January 2007
DOIAbstract
The emergence of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains, i.e. strains resistant at least to isoniazid (INH) and rifampin (RMP), the two most powerful first-line drugs for the treatment of tuberculosis (TB), represents a worldwide health care problem. Patients with MDR strains should receive therapy based on individual drug susceptibility testing (DST) 1 including residual first-line (streptomycin, SM; ethambutol, EMB; and pyrazinamide, PZA) and second-line (ofloxacin, kanamycin, capreomycin, ethionamide, p-aminosalicylic acid, cycloserine) anti-TB drugs
Add to ORKG